China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for its serum-free iterative rabies vaccine following the acquisition of the Drug Manufacturing License. The unblinded Phase III study results have demonstrated that the product meets the predetermined evaluation criteria for safety, immunogenicity, and immune persistence.
Product Innovation and Market Potential
The serum-free rabies vaccine, with no similar offering approved globally, is poised to become the world’s first of its kind. It offers better safety compared to existing Vero cell rabies vaccines and human diploid rabies vaccines on the market, positioning AIM Vaccine at the forefront of rabies vaccine innovation.-Fineline Info & Tech
Leave a Reply